COVID-19 Treatment in Pregnancy
For pregnant women with mild-to-moderate COVID-19 not requiring supplemental oxygen, supportive care with close monitoring is the primary approach, with consideration of thromboprophylaxis given the increased VTE risk in this population.
Key Management Principles
The available guidelines 1 focus primarily on general pregnancy care during COVID-19 rather than specific antiviral treatments for mild-moderate disease. This reflects the 2020 timeframe when these guidelines were developed, before widespread availability of COVID-19-specific therapeutics.
For Mild-Moderate Disease (No Oxygen Required)
Primary approach:
- Self-isolation according to national guidelines
- Supportive care with symptom management
- Close monitoring for disease progression
- Consider differentials including pulmonary embolism and sepsis, which can mimic COVID-19 symptoms 1
Critical Safety Consideration: Thromboprophylaxis
The most important clinical intervention is VTE risk assessment. Pregnancy itself is a hypercoagulable state, and COVID-19 further increases thromboembolism risk 1. While the guidelines don't specify exact criteria, they emphasize considering low molecular weight heparin prophylaxis based on individual risk factors.
Antiviral Therapy Considerations
Recent evidence suggests antivirals are underutilized in pregnancy. A 2025 US study found only 1.3% of pregnant patients received antiviral treatment compared to 7.3% of non-pregnant women, representing a 67% lower treatment rate 2. This likely reflects clinical inertia rather than evidence-based practice.
For patients with risk factors for progression:
- Nirmatrelvir/ritonavir is first-line when no contraindications exist 3
- Remdesivir has demonstrated safety in pregnancy, with better outcomes when started early (within 5 days of symptoms) 4
- Treatment should be initiated within 5 days of symptom onset for maximum benefit 3
Follow-up Requirements
After symptom resolution:
- Refer for fetal growth surveillance ultrasound 14 days after symptom resolution 1
- This monitors for potential effects on fetal growth
Mental Health and Safeguarding
- Inquire about mental health at every consultation 1
- Maintain usual safeguarding referrals despite assessment challenges
Common Pitfalls to Avoid
Clinical inertia: Don't withhold treatment solely based on pregnancy status 5. Pregnant women with risk factors deserve the same consideration for antiviral therapy as non-pregnant patients.
Missing VTE risk: The dual hypercoagulable state (pregnancy + COVID-19) creates substantial thrombotic risk that must be actively assessed 1.
Delayed antiviral initiation: If antivirals are indicated, they must be started within 5 days of symptom onset 4, 3.
Overlooking alternative diagnoses: Pulmonary embolism and sepsis can present similarly to COVID-19 in pregnancy 1.
Important Caveats
The provided guidelines 1 are from 2020 and predate most COVID-19-specific therapeutics. Current practice should integrate newer evidence on antivirals 4, 2 while maintaining the core principles of VTE prophylaxis and close monitoring established in these guidelines. Vaccination remains the most effective intervention and should be recommended at any stage of pregnancy 5.